Clinical trial
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
NCT00537485 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- December 31, 2009
- Enrollment
- 180 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
early parkinson's disease